Cholinergic Drugs: Risks, Symptoms, and Management Strategies

Authors

  • Prahlad Kumar
  • Kanika Srivastava

Keywords:

Cholinergic drugs, PNS, Neurotransmitters, Sign & symptoms.

Abstract

Cholinergic medications primarily affect the main neurotransmitter in the parasympathetic nervous system (PNS), acetylcholine. They are categorized into two main types: direct-acting and indirect-acting drugs. Direct-acting cholinergic agonists bind directly to muscarinic receptors, exemplified by choline esters (such as acetylcholine, methacholine,
carbachol, bethanechol, tacrine) and alkaloids (including muscarine, pilocarpine, and cevimeline). Indirect-acting cholinergic agents increase acetylcholine availability at cholinergic receptors. Reversible agents (such as physostigmine, neostigmine, pyridostigmine, edrophonium, rivastigmine, donepezil, and galantamine) and irreversible agents (like
echothiophate, parathion, Malathion, diazinon, tabun, sarin, soman, carbaryl, and propoxur) are included in this category. Their use can lead to adverse effects across organs controlled by the parasympathetic
nervous system, highlighting the limitations of cholinergic agonists despite their therapeutic benefits.

How to cite this article:
Kumar P, Srivastava K. Cholinergic Drugs: Risks,
Symptoms, and Management Strategies. J Adv
Res in medc che 2024; 6(1): 21-25.

References

Ehret MJ, Chamberlin KW. Current practices in the treatment of alzheimer disease: where is the evidence after the phase III trials? Clin Ther. 2015; 37(8): 1604-16.

Pepeu G, Giovannini MG. Cholinesterase inhibitors and beyond. Curr Alzheimer Res. 2009; 6(2): 86-96.

Korsten MA, Lyons BL, Radulovic M, et al. Delivery of neostigmine and glycopyrrolate by iontophoresis: a nonrandomized study in individuals with spinal cord injury. Spinal Cord. 2018; 56(3): 212-7.

Ohbe H, Jo T, Matsui H, et al. Cholinergic Crisis Caused by Cholinesterase Inhibitors: a Retrospective Nationwide Database Study. J Med Toxicol. 2018; 14(3): 237-41.

Adeyinka A, Kondamudi NP. StatPearls Publishing; Treasure Island (FL): Mar 24, 2019. Cholinergic Crisis.

Houzé P, Berthin T, Raphalen JH, et al. High dose of pralidoxime reverses paraoxon-induced respiratory toxicity in mice. Turk J Anaesthesiol Reanim. 2018; 46(2): 131-8.

Wiercinski A, Jackson JP. StatPearls Publishing; Treasure Island (FL): Jun 3, 2019. Nerve Agents.

Vanova N, Pejchal J, Herman D, et al. Oxidative stress in organophosphate poisoning: role of standard antidotal therapy. J Appl Toxicol. 2018; 38(8): 1058-70.

Antonijevic E, Kotur-Stevuljevic J, Musilek K, et al. Effect of six oximes on acutely anticholinesterase inhibitor-induced oxidative stress in rat plasma and brain. Arch Toxicol. 2018; 92(2): 745-57.

Malinak D, Nepovimova E, Jun D, et al. Novel group of AChE reactivators-synthesis, in vitro reactivation and molecular docking study. Molecules. 2018; 23(9).

Arsura EL, Brunner NG, Namba T, et al. Adverse cardiovascular effects of anticholinesterase medications. Am J Med Sci. 1987; 293(1): 18-23.

Assis CRD, Linhares AG, Cabrera MP, et al. Erythrocyte acetylcholinesterase as biomarker of pesticide exposure: new and forgotten insights. Environ Sci Pollut Res Int. 2018; 25(19): 18364-76.

Haga T. Molecular properties of muscarinic acetylcholine receptors. Proc Jpn Acad Ser B Phys. Biol Sci. 2013; 89(6): 226-56.

Gorecki L, Korabecny J, Musilek K, et al. Progress in acetylcholinesterase reactivators and in the treatment of organophosphorus intoxication: a patent review (2006-2016). Expert Opin Ther Pat. 2017; 27(9): 971-85.

Jeyaratnam J. Acute pesticide poisoning: a major global health problem. World Health Stat Q. 1990; 43(3): 139-44.

Downloads

Published

2024-11-07